Baird analyst David Rescott raised the firm’s price target on Medtronic (MDT) to $91 from $90 and keeps a Neutral rating on the shares. The firm updated its model following Q4 results and said the MedSurg miss clouds an improving return to stability.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- Medtronic’s Strong Growth and Positive Outlook Reinforce Buy Rating Despite Challenges
- Medtronic Q3 Fiscal 2025 Financial Overview
- Medtronic’s Earnings Call Highlights Consistent Growth
- Medtronic’s Strong Profitability and Growth Prospects Earn Buy Rating from Analyst
- Mixed Indicators Lead to Hold Rating for Medtronic: A Balanced Outlook on Future Prospects